

**Biologics by Design.
Imagine.**

Sutro Biopharma

Management

William J. Newell

Chief Executive Officer

Trevor Hallam, PhD

Chief Scientific Officer

Jay Shukert, MBA

Chief Financial Officer

Henry Heinsohn

Vice President

Development and Manufacturing

Christopher Murray, PhD

Vice President

Research

Lesley Stolz, PhD

Vice President

Business Development

Board of Directors

Leon Chen, PhD

Skyline Ventures

Bryan Lawlis, PhD

Itero Biopharmaceuticals

David Mack, PhD

Alta Partners

William J. Newell

Sutro Biopharma, Inc.

Daniel H. Petree

P2 Partners

Michael Ross, PhD

SV Life Sciences

Armen Shanafelt, PhD

Lilly Ventures

James R. Swartz, ScD

Stanford University

Investors

Alta Partners

Amgen Ventures

Lilly Ventures

Skyline Ventures

SV Life Sciences

About Sutro Biopharma

Sutro Biopharma is a biopharmaceutical company that develops and designs novel protein therapeutics and biosuperiors that have site-directed modifications, including modifications incorporating non-natural amino acids. Sutro's biochemical protein synthesis technology enables the rapid and systematic exploration of many protein drug variants to identify drug candidates including protein therapeutics that cannot be produced using conventional methods.


Sutro is collaborating with select pharmaceutical and biotechnology companies in the development of novel protein therapeutics that cannot be designed, produced or studied with current technologies. Sutro's technology is based on James R. Swartz's, Sc.D., patented Open Cell Free Synthesis (OCFS) technology.

Sutro Biopharma was founded in 2003 with corporate headquarters in South San Francisco, California.

Sutro's Biochemical Protein Synthesis Technology

Sutro Biopharma's scalable biochemical protein synthesis technology platform enables the design and production of protein therapeutics and biosuperiors that cannot be produced or studied with other technologies. The technology platform unlocks new therapeutic opportunities through a unique synthesis approach and the introduction of site-specific chemical modifications, including non-natural amino acids, to improve therapeutic performance.

Conventional methods for expressing proteins depend on utilizing living cell lines that originate from bacteria, yeast, insects, plants, or mammals. Currently, cell-based technologies exhibit several limitations in respect to synthesis of proteins, including those with novel chemical modifications, and many biologics can't be developed in these systems.



Sutro's technology has been designed to promote proper folding by optimizing synthesis and the chemical and physical environment to maintain homeostasis throughout the expression process. The components of the system have been selected to closely mimic the environment of the cellular folding compartment. In addition, the open architecture of the system easily allows additions of exogenous chemical species as well as catalysts to promote folding in the cases where those additions are needed.

Sutro Biopharma

Sutro's technology enables:

- The synthesis of many proteins and families of proteins that are of interest to researchers but have been inaccessible using current cellular expression technologies
- Rational combinatorial expression optimization
- Linearly scalable production of hundreds of liters: direct, fast and predictable advancement from bench to GMP production
- The rapid incorporation of a wide variety of non-natural amino acid side chains, leading to true optimization of protein properties in a combinatorial fashion

Inaccessible Proteins

There are many proteins of therapeutic interest that are inaccessible because they are not expressed by a cell, are not soluble when expressed, cannot be isolated or are modified by the cellular expression host in an undesirable way. Sutro can use its biochemical protein synthesis platform to rapidly explore the expression and folding of these inaccessible proteins.

Biosuperiors and Novel Optimized Proteins

Sutro is using a dual approach that includes rational protein design as well as the use of focused libraries of non-natural amino acids to rapidly explore and identify protein therapeutics with improved properties. The incorporation of non-natural amino acids can change the characteristics of proteins, including ligand binding, catalytic efficiency and substrate specificity, stability, spectroscopic properties and folding behavior. In respect to drug development, these modifications provide possibilities to develop biosuperiors that have superior pharmacological properties, including improved safety profiles, longer half-life and enhanced activity. Sutro is applying its technology to address known product issues of current therapeutics.

Sutro Biopharma's Pipeline

Sutro Biopharma is currently developing several therapeutic proteins with its biochemical protein synthesis platform. Sutro's lead product is a biosuperior that takes advantages of Sutro's *in vitro* non-natural amino acid incorporation technology.

Partnering with Sutro Biopharma

Partners have the opportunity to collaborate with Sutro Biopharma on the company's developing pipeline, or to pursue new drug programs using Sutro's Biochemical Protein Synthesis technology to create novel biosuperiors. For information about partnering opportunities contact Lesley Stolz: lstolz@sutro.bio.com

